Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 409

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 409
---
 to one Ordinary Share of £0.001 each and 19 ‘B’ Deferred Shares of £0.001 each. The ‘B’
Deferred Shares have limited rights and are effectively valueless. The previously issued Deferred Shares were redesignated ‘A’
Deferred Shares.

On 5 July 2023 the Company
effected a ratio change in the number of Ordinary Shares represented by ADSs from five Ordinary Shares per ADS to 400 Ordinary Shares
per ADS.

On 26 May 2023 the Company entered into Private Placement
and on 21 December 2023 the Company entered into a Registered Offering. As no share premium was recognised in relation to these transactions
the transaction costs have been charged to retained earnings.

| F-68 |

| 21 | Share capital (continued) |

During the year the Company issued the following warrants
over ADSs, and these were recognised in the warrant reserve until exercise:

| Schedule of warrant reserve recognize    |     |   | Pre-Funded 
   Warrants |   |     |   | Series A 
 Warrants |   |     |   | Series B 
 Warrants |   |     |   | Series C 
 Warrants |   |
|:-----------------------------------------|:----|:--|-----------:|:--|:----|:--|---------:|:--|:----|:--|---------:|:--|:----|:--|---------:|:--|
| Exercise price                           |     | £ |     0.0001 |   |     | $ |   214.40 |   |     | $ |   214.40 |   |     | $ |    16.00 |   |
| As at 1 January 2023                     |     |   |          – |   |     |   |        – |   |     |   |        – |   |     |   |        – |   |
| Issued:                                  |     |   |            |   |     |   |          |   |     |   |          |   |     |   |          |   |
| Private Placement February 2023          |     |   |    155,461 |   |     |   |   32,327 |   |     |   |   48,491 |   |     |   |        – |   |
| Registered Direct Offering May 2023      |     |   |          – |   |